Overall, the proportions of patients achieving ACR20, ACR50
, and ACR70 increased progressively over time (Figure 2a), accompanied by a decrease in DAS28-ESR and DAS28-CRP scores (Figure 2b) and an increase in the proportion of patients achieving low disease activity (LDA; <3.2) and remission (<2.6) according to both DAS28-ESR and DAS28-CRP criteria (data not shown).
A numerically greater proportion of patients in the tofacitinib 10 mg BID sequence versus tofacitinib 5 mg BID sequence achieved ACR50
(54.1% versus 51.2%) and ACR70 (29.4% versus 25.6%) over the 12-month period in ORAL Sync.
up to week 260 had a 71.7% ACR20 response rate, a 48.6% ACR50
response rate, and a 28.4% ACR70 response.
Additionally, 26.7% of patients taking silibinin with MTX achieved ACR50
compared to 6.6% in the placebo group (p = 0.142).
and ACR70 responses are similar to the ACR20 response, but denote 50 percent and 70 percent improvements, respectively.
The combination of TwHF plus methotrexate was the most effective, with an ACR50
response rate of 76.8%, the investigators said (Ann.
Results showed that iguratimod obviously improved ACR20 and ACR70 at 24 weeks, and patients' health assessment questionnaire (HAQ) score showed reduced rest pain, tender joint count, and swollen joint count; lowered CRP level and ESR; and lowered physician and patient global assessment level of disease activity, but ACR50
at 24 weeks has no significant difference.
78.6 percent of patients achieved at least 20 percent improvement in the ACR criteria (ACR20) 55.5 percent achieved at least 50 percent improvement in the ACR criteria (ACR50
) 32.8 percent achieved at least 70 percent improvement in the ACR criteria (ACR70) 71.2 percent achieved a Disease Activity Score 28 [DAS28 (CRP) <3.2] 42.4 percent achieved a Health Assessment Questionnaire Disability Index (HAQ-DI) <0.5
Secondary endpoints include improvements in DAS28, ACR50
and ACR70 rates.
Additionally, 33% of patients reported ACRS0 at 24 weeks and 41% reported ACR50
at 48 weeks of treatment.
The earliest use of an index was defined by the American College of Rheumatology (ACR) as a 20%, 50%, or 70% improvement in swollen and tender joint count plus 3 of the other 5 measures, known as ACR20, ACR50
and ACR70 responses (23, 61).